secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2025-07-02T23:59:59+00:00
Accession:  0000950170-25-093007
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shareholders approve 19.5M share increase to 2021 Equity Plan at annual meeting
-------------------------------------------------------------------------------

- Shareholders approved amendment increasing common shares reserved under 2021 Equity Plan by 19,500,000.
- All seven director nominees elected: Mulroy, Amin, Andrews, Russell, Bradsher, Culley, Jayasuriya.
- Ratification of Baker Tilly as auditor for FY2025 received ~159M votes for, ~912K against.
- Advisory say-on-pay approved with ~96M votes for, ~3.8M against, ~612K abstentions.
- EIP Amendment approved with ~88.6M for, ~11.6M against, ~351K abstentions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000095017025093007/0000950170-25-093007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000095017025093007/lctx-20250626.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-093007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer